Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistGrupo Asimex de Mexico SA de CV, a pharmaceutical company, received an FDA Warning Letter on November 6, 2020, regarding drug products. Based on the limited metadata available, the specific violations cannot be detailed as the subject line information is not provided. This warning indicates the company's operations fell short of FDA regulatory requirements for drug manufacturing or distribution, though the particular deficiencies and the specific FDA office issuing the letter are not identified in this metadata summary.